FDA Reauthorization Act (FDARA) signed into law
On August 18, 2017, the President signed into law the Food and Drug Administration Reauthorization Act (FDARA), which revises and extends FDA’s user-fee programs for prescription drugs, medical devices, generic drugs and biosimilar products. Reauthorization of these user-fee programs allows the agency to continue fulfilling its mission of protecting and promoting public health. It also provides FDA with the necessary resources to increase regulatory efficiency and speed the availability of innovative, safe and effective medical products.
To learn more, please visit: Food and Drug Administration Reauthorization Act (FDARA).
To learn more, please visit: Food and Drug Administration Reauthorization Act (FDARA).
No hay comentarios:
Publicar un comentario